Mortality in IPF (GAP Index)

Estimate mortality in idiopathic pulmonary fibrosis

The global unit selector only affects unanswered questions
1.Gender?
2.Age?
3.FVC?
4.DLCO?
Created by

1. Gender?

Created by
0/4 completed

About this Calculator

This equation is taken from Ley et al (2012). The GAP Index was derived and validated based on 558 patients with idiopathic pulmonary fibrosis (IPF) from three academic centers in the United States and Italy. The GAP Index was validated at both presentation and during follow-up and can therefore be used throughout the disease course. Additional scoring systems have been developed in IPF, but are not validated, include more complex variables, or lack stage-specific management recommendations.

Clinical implications for the GAP Index were suggested by the authors as follows:

Stage 1:

  • Close monitoring (every 6 mo) for evidence of disease progression
  • Aggressive management of symptoms and comorbid conditions
  • May not require immediate listing for lung transplantation

Stage 2:

  • Close monitoring (every 3–6 mo) for evidence of disease progression
  • Consider listing for lung transplantation based on patient preferences, and evidence of disease progression

Stage 3:

  • Consider immediate listing for lung transplantation if appropriate or palliative care referral

References

Ley B et al.

A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Annals of Internal Medicine 2012 May 15, 156 (10): 684-91

T E King, J A Tooze, M I Schwarz, K R Brown, R M Cherniack

Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

American Journal of Respiratory and Critical Care Medicine 2001 October 1, 164 (7): 1171-81

Wells AU et al.

Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.

American Journal of Respiratory and Critical Care Medicine 2003 April 1, 167 (7): 962-9

du Bois RM et al.

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

American Journal of Respiratory and Critical Care Medicine 2011 August 15, 184 (4): 459-66

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.